Neoadjuvant immunotherapy leads to pathological responses in MMR-proficient and MMR-deficient early-stage colon cancers
The Netherlands Cancer Institute · Oncode Institute · +4 more institutions
Indexed incrossrefpubmed
Abstract
No abstract available for this paper.
Citation impact
1,373
total citations
- FWCI
- 67.14
- Percentile
- 100%
- References
- 51
Citations per year
Authors
28- MCMyriam ChalabiCorresponding
The Netherlands Cancer Institute, Oncode Institute
- LFLorenzo F. Fanchi
The Netherlands Cancer Institute, Oncode Institute
- KKKrijn K. Dijkstra
The Netherlands Cancer Institute, Oncode Institute
- JGJosé G. van den Berg
The Netherlands Cancer Institute
- AGArend G. J. Aalbers
The Netherlands Cancer Institute
Topics & keywords
Topics
Keywords
- Nivolumab
- Medicine
- Ipilimumab
- Oncology
- Tremelimumab
- Internal medicine
- Colorectal cancer
- Immunotherapy
UN Sustainable Development Goals
- Good health and well-being
No related works found for this paper.